Arbutus Biopharma (ABUS) Competitors $3.37 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.32 -0.06 (-1.63%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. ALVO, IMVT, GMTX, BHC, KYMR, KNSA, CPRX, ARWR, OGN, and IBRXShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Alvotech (ALVO), Immunovant (IMVT), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Kiniksa Pharmaceuticals International (KNSA), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), Organon & Co. (OGN), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors Alvotech Immunovant Gemini Therapeutics Bausch Health Cos Kymera Therapeutics Kiniksa Pharmaceuticals International Catalyst Pharmaceuticals Arrowhead Pharmaceuticals Organon & Co. ImmunityBio Alvotech (NASDAQ:ALVO) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Does the media favor ALVO or ABUS? In the previous week, Alvotech had 11 more articles in the media than Arbutus Biopharma. MarketBeat recorded 19 mentions for Alvotech and 8 mentions for Arbutus Biopharma. Alvotech's average media sentiment score of 0.78 beat Arbutus Biopharma's score of 0.69 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 5 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ALVO or ABUS? Alvotech has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Is ALVO or ABUS more profitable? Alvotech has a net margin of 11.26% compared to Arbutus Biopharma's net margin of -352.24%. Alvotech's return on equity of -38.36% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech11.26% -38.36% 9.28% Arbutus Biopharma -352.24%-59.28%-44.11% Do analysts rate ALVO or ABUS? Alvotech currently has a consensus price target of $14.00, suggesting a potential upside of 74.56%. Arbutus Biopharma has a consensus price target of $5.50, suggesting a potential upside of 63.20%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, ALVO or ABUS? Arbutus Biopharma has lower revenue, but higher earnings than Alvotech. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$560.10M4.32-$231.86M$0.2334.87Arbutus Biopharma$6.17M104.70-$69.92M-$0.29-11.62 Do insiders and institutionals hold more shares of ALVO or ABUS? 43.8% of Arbutus Biopharma shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryAlvotech beats Arbutus Biopharma on 9 of the 15 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$645.07M$3.14B$5.72B$9.79BDividend YieldN/A2.22%3.91%4.13%P/E Ratio-11.6221.0331.1425.06Price / Sales104.70285.40416.7890.80Price / CashN/A42.6136.7858.67Price / Book7.848.659.086.18Net Income-$69.92M-$54.65M$3.26B$265.11M7 Day Performance-0.88%6.56%7.39%4.22%1 Month Performance7.32%4.82%4.22%0.77%1 Year Performance-9.16%15.81%30.30%24.69% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.638 of 5 stars$3.37flat$5.50+63.2%-9.2%$645.07M$6.17M-11.6290News CoverageAnalyst RevisionALVOAlvotech2.7826 of 5 stars$8.52+0.7%$14.00+64.3%-38.2%$2.57B$585.60M23.031,032Trending NewsEarnings ReportShort Interest ↓IMVTImmunovant2.8997 of 5 stars$14.76-4.5%$35.33+139.4%-49.4%$2.52BN/A-5.39120News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionGMTXGemini TherapeuticsN/A$58.03+1.7%N/A+23.9%$2.51BN/A-58.0330BHCBausch Health Cos3.6143 of 5 stars$6.68+16.1%$9.00+34.8%+45.5%$2.47B$9.63B25.6820,700News CoveragePositive NewsInsider TradeOptions VolumeGap UpHigh Trading VolumeKYMRKymera Therapeutics2.7995 of 5 stars$37.68-7.2%$59.11+56.9%-2.7%$2.45B$47.07M-12.15170Trending NewsEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeKNSAKiniksa Pharmaceuticals International2.6236 of 5 stars$32.74+1.8%$41.17+25.7%+28.4%$2.43B$423.24M818.70220Insider TradeCPRXCatalyst Pharmaceuticals4.8865 of 5 stars$19.68-0.9%$33.20+68.7%+1.8%$2.41B$491.73M11.9380Positive NewsARWRArrowhead Pharmaceuticals4.2046 of 5 stars$17.21+4.8%$43.14+150.7%-9.6%$2.38B$545.21M-13.45400Trending NewsInsider TradeAnalyst RevisionOGNOrganon & Co.4.6962 of 5 stars$9.00-2.4%$18.00+100.0%-53.7%$2.34B$6.28B3.354,000Positive NewsIBRXImmunityBio2.2657 of 5 stars$2.47+1.2%$12.25+396.0%-36.4%$2.33B$56.60M-5.15590News CoverageAnalyst ForecastOptions Volume Related Companies and Tools Related Companies ALVO Alternatives IMVT Alternatives GMTX Alternatives BHC Alternatives KYMR Alternatives KNSA Alternatives CPRX Alternatives ARWR Alternatives OGN Alternatives IBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access